Angiopoietin-2, endothelial dysfunction and renal involvement in patients with systemic lupus erythematosus

Journal of Nephrology

Volumn 25, Issue 4, 2012, Pages 541-550

  El Banawy, Hisham S ^a   Gaber, Eman W ^b   Maharem, Dalia A ^b   Matrawy, Khaled A ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Angiopoietin 2; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

ANGIOPOIETIN 2; AZATHIOPRINE; CHLOROQUINE; CREATININE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATHOGENESIS; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANGIOPOIETIN-2; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BIOPSY; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CREATININE; EGYPT; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; PROTEINURIA; ROC CURVE; SEVERITY OF ILLNESS INDEX; UP-REGULATION; VASODILATION; YOUNG ADULT;

EID: 84859646862     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000030     Document Type: Article

References (58)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-939.
2. Haubitz M. New and emerging treatment approaches to lupus. Biologics. 2010;4:263-271.
3. Full LE, Ruisanchez C, Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2009;11(2): 211-217.
4. Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J. Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopa-thy. Arthritis Rheum. 2001;44(5):1203-1208.
5. Kluz J, Kopeć W, Jakobsche-Policht U, Adamiec R. Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis. Int Angiol. 2009;28(3): 192-201
6. Fiedler U, Augustin HG. Angiopoietins: a link between an-giogenesis and inflammation. Trends Immunol. 2006;27(12): 552-558.
7. Fiedler U, Krissl T, Koidl S, et al. Angiopoietin-1 and angio-poietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem. 2003;278(3):1721-1727.
8. Brindle N P, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res. 2006;98(8): 1014-1023.
9. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004;103(11):4150-4156.
10. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardio-vasc Res. 2001;49(3):659-670.
11. Molino C, Fabbian F, Longhini C. Clinical approach to lupus nephritis: recent advances. Eur J Intern Med. 2009;20(5): 447-453.
12. Kümpers P, David S, Haubitz M, et al. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Ann Rheum Dis. 2009;68(10):1638-1643.
13. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Review: lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus. 2010;19(5):557-574.
14. Davidson A, Aranow C. Lupus nephritis: lessons from murine models. Nat Rev Rheumatol. 2010;6(1):13-20.
15. Ichinose K, Maeshima Y, Yamamoto Y, et al. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006;55(5):1232-1242.
16. Yuan HT, Tipping PG, Li XZ, Long DA, Woolf AS. Angiopoietin correlates with glomerular capillary loss in anti-glomer-ular basement membrane glomerulonephritis. Kidney Int. 2002;61(6):2078-2089.
17. Morović-Vergles J, Salamon L. Lupus nephritis. Reumatizam. 2009;56(2):34-40.
18. Seshan SV, Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glo-merulonephritis: advances and implications. Arch Pathol Lab Med. 2009;133(2):233-248.
19. Baglio V, Gharbiya M, Balacco-Gabrieli C, et al. Choroidopa-thy in patients with systemic lupus erythematosus with or without nephropathy. J Nephrol. 2011;24(4):522-529.
20. Petri M. Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am. 2005;31(2): 245-254, vi.
21. Jane C, David J. Lupus nephritis. Medicine. 2003;31(7): 101-104.
22. Burtis C, Ashwood E, Bruns D. Tietz textbook of clinical chemistry. 4th ed. Philadelphia, PA: Saunders; 2006:797-799, 808-815.
23. Lewis SM, Bain BJ, Bates I. Dacie and Lewis: practical hae-matology. 9th ed. London: Harcourt; 2001:30-41.
24. Smolen JS, Breedveld FC, Schiff MH. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;32(2):244-257.
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
26. Yates JR, Sepp T, Matharu BK, et al; Genetic Factors in AMD Study Group. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357(6): 553-561.
27. Lukasz A, Hellpap J, Horn R, et al. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Crit Care. 2008;12(4):R94-R99.
28. Chang E, Abrahamowicz M, Ferland D, Fortin PR, For. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. J Clin Epidermal. 2002; 55(5):488-497.
29. O'Leary DH, Polak J F. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol. 2002;90(10)(10C):18L-21L.
30. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828): 1111-1115.
31. Quyyumi AA. Prognostic value of endothelial function. Am J Cardiol. 2003;91(12A)(Suppl):19H-24H.
32. Weening JJ, D'Agati VD, Schwartz MM, et al; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-530.
33. Zappitelli M, Duffy CM, Bernard C, Gupta IR. Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis. Pediatr Nephrol. 2008;23(1):83-91.
34. Kuryliszyn-Moskal A, Klimiuk PA, Ciolkiewicz M, Sierakowski S. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus. J Rheumatol. 2008;35(7):1307-1313.
35. Tani C, Mosca M, d'Ascanio A, et al. Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD. Reumatismo. 2006;58(3):212-218.
36. Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol. 2002;29(2):292-297.
37. El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation. 2004;110(4):399-404.
38. Turner E, Dishy V, Chung C P, et al. Endothelial function in systemic lupus erythematosus: relationship to disease activity, cardiovascular risk factors, corticosteroid therapy, and coronary calcification. Vasc Health Risk Manag. 2005;1(4): 357-360.
39. Piper MK, Raza K, Nuttall SL, et al. Impaired endothelial function in systemic lupus erythematosus. Lupus. 2007;16(2): 84-88.
40. Kiss E, Soltesz P, Der H, et al. Reduced flow-mediated va-sodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun. 2006;27(4):211-217.
41. Cacciapaglia F, Zardi EM, Coppolino G, et al. Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. Lupus. 2009;18(3): 249-256.
42. Fischer K. Risk factors of thickened intima-media and atherosclerotic plaque development in carotid arteries in patients with systemic lupus erythematosus. Ann Acad Med Stetin. 2008;54(2):22-32.
43. Ghosh P, Kumar A, Kumar S, Aggarwal A, Sinha N, Misra R. Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus. Clin Rheumatol. 2009;28(11):1259-1265.
44. Narshi CB, Giles I P, Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus. 2011;20(1):5-13.
45. Kümpers P, Hellpap J, David S, et al. Circulating angiopoi-etin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. Nephrol Dial Transplant. 2009;24(6):1845-1850.
46. Mart ON, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. AntiC1q Abs in nephritis: correlation between titres and renal disease activity and positive predictive value in SLE. Ann Rheum Dis. 2005;64:444-448.
47. DeBusk LM, Chen Y, Nishishita T, Chen J, Thomas JW, Lin PC. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum. 2003;48(9):2461-2471.
48. Aplin AC, Gelati M, Fogel E, Carnevale E, Nicosia R F. An-giopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis. Physiol Genomics. 2006;27(1):20-28.
49. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12(2): 235-239.
50. Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007;109(12): 5276-5285.
51. Anuradha S, Mohan V, Gokulakrishnan K, Dixit M. Angio-poietin-2 levels in glucose intolerance, hypertension, and metabolic syndrome in Asian Indians (Chennai Urban Rural Epidemiology Study-74). Metabolism. 2010;59(6):774-779.
52. Lieb W, Zachariah J P, Xanthakis V, et al. Clinical and genetic correlates of circulating angiopoietin-2 and soluble Tie-2 in the community. Circ Cardiovasc Genet. 2010;3(3): 300-306.
53. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and angiogenesis. Curr Pharm Des. 2003;9(21): 1733-1744.
54. David S, Kümpers P, Lukasz A, et al. Circulating angiopoi-etin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant. 2010;25(8):2571-2576.
55. Davis B, Dei Cas A, Long DA, et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol. 2007;18(8): 2320-2329.
56. Camici M. Renal glomerular permselectivity and vascular endothelium. Biomed Pharmacother. 2005;59(1-2):30-37.
57. Sun H, Zheng JM, Chen S, Zeng CH, Liu ZH, Li LS. Enhanced expression of ANGPTL2 in the microvascular lesions of diabetic glomerulopathy. Nephron Exp Nephrol. 2007;105(4): e117-e123.
58. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 2005;118(Pt 4):771-780.